Area of research
Pulmonary and Respiratory Medicine · Emergency Medical Services
Research interest
Research interests include Medicine, Cystic fibrosis, Ivacaftor, Cystic fibrosis transmembrane conductance regulator, Internal medicine, and Tolerability.
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment
Remote endpoints for clinical trials in cystic fibrosis: Report from the U.S. CF foundation remote endpoints task force
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study
Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation
Airway microbiota across age and disease spectrum in cystic fibrosis
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR
Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis
Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial
Clinical outcomes after initial <i>pseudomonas</i> acquisition in cystic fibrosis